BioEclipse Therapeutics™ to Present at Virtual H.C. Wainwright 23rd Annual Global Healthcare Conference

MOUNTAIN VIEW, Calif., Sept. 10, 2021 /PRNewswire/ -- BioEclipse Therapeutics™, a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on its patented natural killer T-cell (NKT)/oncolytic virus technology platform, announced today that Pamela Reilly Contag, Ph.D., Founder and CEO, will present at the H.C. Wainwright Annual Global Healthcare Conference taking place virtually September 13-15, 2021. The prerecorded presentation will be available online starting at 7 a.m. ET on September 13, 2021 and can be accessed via the conference's virtual platform by registered conference attendees.

Dr. Contag and members of the BioEclipse management team are also hosting one-on-one meetings with registered investors and biopharmaceutical industry executives.

During her presentation, Dr. Contag will provide an overview of BioEclipse's business and highlight the company's proprietary technology platform and the role it plays in the development of a new class of immune therapeutics. These therapies pair the tumor-locating ability of cytokine-induced killer (CIK) cells with the power of an oncolytic virus that selectively infects and kills malignant cells to create a multi-modal therapy that overcomes the limitations that have previously hobbled the efficacy of cellular and oncolytic viral therapies.

Details of the presentation are as follows: 

About BioEclipse Therapeutics™
BioEclipse Therapeutics™ is an emerging, clinical-stage biopharmaceutical company using a novel platform that combines immune cells and an oncolytic virus to expand treatment options for patients with refractory solid tumors. Our focus is currently on treatment of recurring cancers with our unique multi-mechanistic approach that could address cancers believed to be untreatable. BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers. For more information, visit www.bioeclipse.com.

Contact:
Tiberend Strategic Advisors, Inc.
Johanna Bennett (Media)
212-375-2686 
[email protected]

SOURCE BioEclipse Therapeutics